The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid a notable wave of consolidation among small-cap biotech firms, Scancell Holdings PLC (SCLP) confirmed it is in advanced reverse merger negotiations with US-listed Neuphoria Therapeutics. The company stated in a response to media speculation that the deal would be an all-share transaction, without disclosing valuation or financial terms.
The announcement comes as the biotech sector sees a surge in M&A activity, with smaller firms seeking alternative funding routes. Reverse mergers are often used as a faster path to listing on larger exchanges while avoiding an IPO. Scancell has focused on immuno-oncology therapies, while Neuphoria develops treatments for neurological disorders.
No timeline has been set for completion, but investors are watching for upcoming regulatory filings. On the technical side, no closing price was available for SCLP due to limited trading in London. The final deal terms, including the exchange ratio, are expected to determine the stock's near-term trajectory.
Sign in to access this content
Sign In